BACKGROUND: Minimal residual disease (MRD) assessment predicts survival for patients with newly diagnosed acute lymphoblastic leukemia (ALL). Its significance in relapsed/refractory ALL is less clear. METHODS: This study identified 78 patients with relapsed/refractory B-cell ALL who achieved a morphologic response with inotuzumab ozogamicin (n 5 41), blinatumomab (n 5 11), or mini-hyperfractionated cyclophosphamide, vincristine, and doxorubicin plus inotuzumab (n 5 26) during either salvage 1 (S1; n 5 46) or salvage 2 (S2; n 5 32) and had undergone an MRD assessment by multiparameter flow cytometry at the time of remission. RESULTS: MRD negativity was achieved in 41 patients overall (53%). The MRD negativity rate was 57% in S1 and 47% in S2. Among patients in S1, achieving MRD negativity was associated with longer event-free survival (EFS; median, 18 vs 7 months; 2-year EFS rate, 46% vs 17%; P 5.06) and overall survival (OS; median, 27 vs 9 months; 2-year OS, 52% vs 36%; P 5.15). EFS and OS were similar in S2, regardless of the MRD response. Among MRD-negative patients who underwent allogeneic stem cell transplantation (SCT), EFS and OS were superior for those who underwent SCT in S1 rather than S2 (P 5.003 and P 5.04, respectively). Patients in S1 who achieved MRD negativity and subsequently underwent SCT had the best outcomes with a 2-year OS rate of 65%. CONCLUSIONS: Patients with relapsed/refractory ALL who achieve MRD negativity in S1 can have long-term survival. Patients in S2 generally have poor outcomes, regardless of their MRD status. Cancer 2017;123:294-302.
INTRODUCTION
In patients with newly diagnosed acute lymphoblastic leukemia (ALL), minimal residual disease (MRD) assessment after induction chemotherapy can help to determine the prognosis and risk-stratify patients for appropriate postremission therapies. [1] [2] [3] [4] However, many patients still relapse, and their prognosis is dismal. 5, 6 New monoclonal antibody therapies such as the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin and the anti-CD19 bispecific T-cell engager blinatumomab, either alone or in combination with cytotoxic chemotherapy, have recently shown promise for patients with relapsed or refractory ALL and have improved outcomes in comparison with conventional chemotherapy, and some patients have experienced long-term survival.
(SCT), 12 and in 1 study, SCT appeared to decrease the risk for relapse or death in children who had an unsatisfactory MRD response to salvage therapy. 13 For adults with ALL, the prognostic significance of MRD in relapsed/refractory ALL has been primarily reported in the context of individual studies using novel salvage treatments. Patients with relapsed/refractory ALL treated with blinatumomab who achieved MRD negativity had longer survival than patients who remained MRDpositive. 14, 15 In 1 study of inotuzumab as salvage therapy, the achievement of MRD negativity was associated with a longer remission duration. 16 To clarify the prognostic impact of MRD assessment in adults with relapsed/refractory ALL, we performed a retrospective analysis of 78 patients treated at our institution who achieved remission with either their first or second salvage therapy. Patients were treated with inotuzumab ozogamicin, blinatumomab, or minihyperfractionated cyclophosphamide, vincristine, and dexamethasone plus inotuzumab (HCVD1ino) and had MRD assessed at the time of the response.
MATERIALS AND METHODS

Patients and Treatments
Between June 2010 and May 2015, 130 adolescent and adult patients at our institution with relapsed/refractory B-cell ALL received treatment in either salvage 1 (S1; n 5 68) or salvage 2 (S2; n 5 62) with inotuzumab ozogamicin, blinatumomab, or HCVD1ino. The inotuzumab and blinatumomab regimens have been previously published. 14, 16 The HCVD1ino regimen was delivered similarly to hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) 17 but used cyclophosphamide and dexamethasone with 50% dose reductions and omitted anthracyclines; on alternating cycles, methotrexate (250 mg/m 2 ; 75% dose reduction) and cytarabine (4 doses at 0.5 g/m 2 ; 83% dose reduction) were given. Inotuzumab was administered on day 3 of the first 4 cycles of therapy at a dose of 1.3 to 1.8 mg/m 2 for the first cycle and at a dose of 0.8 to 1.3 mg/m 2 for subsequent cycles (depending on the time at which the patient was enrolled). The treatment protocols were approved by the institutional review board of The University of Texas MD Anderson Cancer Center. Informed consent was obtained according to the Declaration of Helsinki and our institutional guidelines. Seventy-five patients (58%) received inotuzumab, 35 (27%) received HCVD1ino, and 20 (15%) received blinatumomab (Fig. 1) . SCT was performed on the basis of donor availability and at the discretion of the treating physician. Among the initial 130 patients, 78 (60%) achieved a morphological response with a median time to best response of 30 days (range, 13-99 days); these 78 patients are the subject of this analysis.
Response Definitions
A complete response (CR) was defined as the presence of <5% blasts in the bone marrow aspirate with >1 3 10 9 /L neutrophils and 100 3 10 9 /L platelets in the peripheral blood and with no evidence of extramedullary disease. A complete response with inadequate platelet recovery (CRp) was defined as a response meeting the criteria for CR but with a platelet count <100 3 10 9 /L. A complete response with inadequate count recovery (CRi) was defined as < 5% blasts in the bone marrow aspirate and no evidence of extramedullary disease without the criteria for either CR or CRp being met. Relapse was defined as the recurrence of 5% blasts in a bone marrow aspirate or the presence of extramedullary disease. Event-free survival (EFS) was calculated from the time of treatment initiation until treatment failure, relapse, or death from any cause. Overall survival (OS) was calculated from the time of treatment initiation until death from any cause. Survival estimates were not censored at the time of SCT.
MRD
MRD by multiparameter flow cytometry (MFC) was performed on remission bone marrow specimens at the time of achievement of CR/CRp/CRi. The MRD assessment was performed initially at approximately 4 weeks and then at least every 2 cycles of therapy. The MRD assay used a 6-color panel as previously described. 18 For patients treated with inotuzumab, the initial gate was set on CD19 1 cells with low side-scatter light. In all cases, the leukemic blasts had aberrations in markers other than CD22, and CD22 expression was not included in the analysis for MRD. For patients treated with Figure 1 . Study population. CR indicates complete response; CRi, complete response with inadequate count recovery; CRp, complete response with inadequate platelet recovery; hyper-CVD, hyperfractionated cyclophosphamide, vincristine, and dexamethasone; ino, inotuzumab; S1, salvage 1; S2, salvage 2.
blinatumomab, the initial gate was set on CD10 1 cells with low side-scatter light. MRD positivity was defined on MFC scatter plots as a cluster of at least 20 cells showing altered expression of 2 or more antigens. The sensitivity of this MRD assay is 0.01%.
Statistical Methods
Patient characteristics were summarized as medians and ranges for continuous variables and as frequencies and percentages for categorical variables. Associations between categorical and continuous variables were assessed with chi-square tests. EFS and OS were calculated with Kaplan-Meier estimates; EFS and OS estimates were compared with the log-rank test. To evaluate the impact of SCT on survival outcomes, a 2-month landmark analysis was performed from which patients who relapsed or died within 2 months of achieving remission were excluded. By excluding patients with early death or relapse, this method allowed a more accurate determination of the potential impact of SCT on outcomes.
RESULTS
Baseline Characteristics
The baseline characteristics of the study group are shown in Table 1 . The median age was 38 years (range, 18-87 years). Of the 78 patients who achieved remission with salvage therapy, 46 (59%) were in S1, and 32 (41%) were in S2. Forty-one patients (53%) received inotuzumab, 11 (14%) received blinatumomab, and 26 (33%) received HCVD1ino. Nineteen patients (24%) had a normal karyotype at the time of salvage treatment, 4 (5%) had t(9;22), and 7 (9%) had t(4;11). Twenty-eight patients (36%) were refractory to previous therapy, and 11 (14%) had undergone prior SCT. Compared with patients in S1, patients in S2 had lower platelet counts (P 5 .03), were more likely to have been refractory to their last therapy (P < .001), and were less likely to receive HCVD1ino (P 5 .006).
Forty-eight patients (62%) received hyper-CVADbased chemotherapy as their initial treatment, 11 (14%) received a Berlin-Frankfurt-M€ unster-based regimen, and 19 (24%) received other multiagent chemotherapy regimens. For the patients in S2, previous salvage regimens included multiagent chemotherapy in 21 (66%), blinatumomab in 2 (6%), chimeric antigen receptor T cells in 1 (3%), moxetumomab pasudotox in 1 (3%), ponatinib in 1 (3%), and other investigational agents in 6 (19%) . No patients in the study population received prior inotuzumab, either alone or in combination with other agents.
MRD Response by Treatment, Disease Status, and Line of Therapy
The median number of cycles to the best response was 1 (range, 1-3). Fifty-two patients (67%) achieved their best response after 1 cycle of salvage therapy. MRD negativity was achieved by 41 patients (53%). The rates of MRD negativity were similar among patients who achieved their best response after 1 cycle and patients who achieved their best response after 2 or more cycles (52% vs 54%, respectively). MRD negativity rates for CR, CRp, and CRi patients were 57%, 53%, and 16%, respectively. Among patients who achieved remission, MRD negativity was noted in 17 patients (41%) treated with inotuzumab, in 8 patients (73%) treated with blinatumomab, and in 16 patients (62%) treated with HCVD1ino (P 5 .10). Eight of 11 patients (73%) with prior SCT achieved MRD negativity. MRD negativity rates were similar for patients with refractory disease and patients with relapsed disease (54% vs 51%, respectively; P 5 .83). Twenty-six patients (57%) in S1 and 15 (47%) in S2 became MRD-negative (P 5 .40). Among the 46 patients in S1, MRD negativity was achieved by 9 patients (43%) who received inotuzumab, 3 (75%) who received blinatumomab, and 14 (67%) who received HCVD1ino. Among the 32 patients in S2, MRD negativity was achieved by 8 (40%), 5 (71%), and 2 (40%), respectively. Four patients with Philadelphia chromosome-positive ALL were evaluated for MRD, and 3 of them achieved MRD negativity by MFC. Two of these 3 MRD-negative patients also underwent concomitant BCR-ABL1 testing by polymerase chain reaction with detectable BCR-ABL1/ABL1 ratios of 0.09% and 0.27%.
Survival Outcomes by the MRD Response
Within a median follow-up duration of 27 months (range, 6-55 months), 38 of the 78 evaluable patients (49%) had relapsed. Twenty-one of the patients who relapsed (55%) were MRD-negative after salvage treatment, and 17 (45%) were MRD-positive after salvage treatment. The median EFS was 12 months for patients who were MRD-negative and 6 months for those who were MRDpositive; the 2-year EFS rates were 31% and 12%, respectively (P 5 .09; Fig. 2A ). Fifty-one patients (65%) died: 25 of those who achieved MRD negativity (61%) and 26 of those who remained MRD-positive (70%). The median OS was 17 months for patients who were MRDnegative and 9 months for those who were MRD-positive; the 2-year OS rates were 40% and 26%, respectively (P 5 .18; Fig. 2B ).
Impact of Salvage Status on Outcomes
When patients were stratified according to the salvage status, a differential impact on survival was observed (Fig. 3 ). As expected, for patients who achieved MRD negativity, those in S1 had significantly longer EFS (median, 18 vs 5 months; P 5 .001) and OS (median, 27 vs 7 months; P 5 .01) than those in S2 (Fig. 3A) . In contrast, for patients who remained MRD-positive, EFS and OS were similar, regardless of the salvage status (P 5 .41 and P 5 .39, respectively). Among patients in S1, those who achieved MRD negativity had longer EFS (median, 18 vs 7 months; 2-year EFS rate, 46% vs 17%; P 5 .06) and OS (median, 27 vs 9 months; 2-year OS, 52% vs 36%; P 5 .15) than those who were MRD-positive (Fig. 3B ). In contrast, for patients in S2, EFS and OS were similar among MRDnegative and MRD-positive patients (P 5 .88 and P 5 .99, respectively).
Among the 11 patients with prior SCT, long-term survival was observed in a subgroup of patients who achieved MRD negativity. All 3 patients with prior SCT who remained MRD-positive died with a median OS of 8 months, whereas the median OS was 39 months for the 8 patients with prior SCT who achieved MRD negativity (P 5 .04). The median EFS was also longer for the MRDnegative group versus the MRD-positive group (18 vs 8 months; P 5 .01). Four of the 8 MRD-negative patients were still; 2 subsequently underwent SCT. The median survival duration of these patients was 29 months (range, 27-55 months).
Impact of SCT and MRD Status on Outcomes
Fourteen patients (18%) relapsed or died within 2 months of achieving remission and were excluded for the purposes of the landmark analysis. Of the 64 remaining patients, 40 (62%) were in S1, and 24 (38%) were in S2.
Overall, 42 of these patients (66%) underwent SCT with a median time to SCT of 2 months; 20 of these patients had achieved MRD negativity and 22 had remained MRD-positive at the time of their response to the salvage treatment. The rates of SCT were similar among MRDnegative and MRD-positive patients (63% and 69%, respectively) and among those in S1 and S2 (65% and 67%, respectively).
Among the 64 patients included in the landmark analysis, 13 were still alive with >2 years of follow-up. Long-term survival was observed in all groups of patients, regardless of the salvage treatment (n 5 6 for inotuzumab, n 5 3 for blinatumomab, and n 5 4 HCVD1ino), the salvage status (n 5 10 for S1 and n 5 3 for S2), or the MRD status (n 5 9 for a negative status and n 5 4 for a positive status). Eight of these 13 patients (62%) had undergone SCT.
Overall, EFS and OS did not differ between patients who did undergo SCT and patients who did not undergo SCT (P 5 .84 and P 5 .97, respectively). Nevertheless, a clear trend for improved long-term outcomes with SCT was seen, and the small numbers may account for the lack of significance. Among patients who achieved MRD negativity, the median EFS was 17 months and 12 months for patients who underwent SCT and patients who did not, respectively, and the corresponding 2-year EFS rates were 46% and 28% (P 5 .24). The median OS values were 24 and 23 months, respectively, and the 2-year OS rates were 55% and 46%, respectively (P 5 .41). For MRD-positive patients, the median EFS values were 6 and 9 months, respectively, and the 2-year EFS rates were 11% and 25%, respectively (P 5 .48). Similarly, among MRD-positive patients, the median OS values were 10 and 9 months, respectively, and the 2-year OS rates were 23% and 36%, respectively (P 5 .56). Among patients who underwent SCT, those who were MRD-negative at response had significantly longer EFS and OS than those who were MRDpositive (P 5 .006 and P 5 .02, respectively).
Effect of the Salvage Status on the Post-SCT Outcomes
When they were stratified according to their salvage status, patients who achieved MRD negativity after S1 treatment and subsequently underwent SCT appeared to have the best outcomes (Fig. 4) . Among the 22 patients who achieved MRD negativity after S1 treatment, the median EFS for those who underwent SCT (n 5 14) was not reached, whereas it was 18 months for those who did not undergo SCT (n 5 8; P 5 .14); the median OS was not reached for those who underwent SCT and was 27 months for those who did not (P 5 .28). EFS and OS were similar among MRD-positive patients, regardless of whether SCT was performed (P 5 .51 and P 5 .53, respectively). Among the 14 patients who achieved MRD negativity after S1 treatment and subsequently underwent SCT, 10 (71%) were still alive with a median follow-up of 24 months (range, 5-55 months). Four patients died: 2 of relapsed ALL, and 2 of complications of graft-versus-host disease.
In contrast, EFS and OS were similar among patients in S2, regardless of the MRD status or SCT (Fig.  5 ). Among MRD-negative patients who underwent SCT, EFS and OS were superior for those who underwent SCT in S1 rather than S2 (P 5 .003 and P 5 .04, respectively). However, EFS and OS were similar among MRDpositive patients who underwent SCT, regardless of the salvage status (P 5 .54 and P 5 .33, respectively).
DISCUSSION
The achievement of MRD negativity in response to frontline chemotherapy is predictive of improved survival among patients with ALL in both pediatric and adult populations. 1, 2, 4, 19 In this study of patients with relapsed/refractory B-cell ALL, we found the achievement of MRD negativity to be associated with improved outcomes even in the salvage setting; this resulted in an approximately 2-fold increase in both EFS and OS in comparison with those patients who remained MRD-positive. The achievement of MRD negativity was seen across treatments and with similar frequencies, regardless of the salvage status or whether the patient had relapsed or was refractory to previous treatment. However, the beneficial prognostic impact of achieving MRD negativity was limited to patients in S1. In particular, we identified a subgroup of patients who achieved MRD negativity in S1 and subsequently received SCT that had excellent long-term outcomes. These findings suggest that MRD assessment plays an important prognostic role in the relapsed/refractory setting, although its utility is strongly influenced by the salvage status.
Despite similar rates of MRD negativity among those in S1 and S2 (57% and 47%, respectively), the MRD status was prognostic only for patients in S1. Among patients in S1, the achievement of MRD negativity was associated with an increase in the median OS and a favorable 2-year OS rate of 52%. In contrast, outcomes were similar among patients in S2, regardless of the MRD status at remission. Notably, those patients who achieved MRD negativity with S1 and subsequently underwent SCT had the best outcome, with 71% of the patients still alive after a median follow-up of 2 years. The survival of patients who achieved MRD negativity in S1 (median OS, 27 months) compares very favorably with the historical median OS of 4 to 5 months reported for adult patients with refractory or first relapsed ALL treated with standard chemotherapy-based salvage regimens. 5, 6 Taken together, these findings suggest that patients with relapsed/refractory ALL who achieve MRD negativity in S1 can have excellent long-term outcomes, especially if salvage SCT is performed.
The finding that the achievement of MRD negativity is an important therapeutic endpoint in S1 but not in S2 raises several intriguing questions. The lack of prognostic significance of MRD negativity by MFC in S2 highlights the need for more sensitive assays to detect MRD. Next-generation sequencing holds promise in identifying MRD with a higher level of sensitivity than MFC, although experience with this approach is relatively limited. 20, 21 In addition, next-generation sequencing has the ability to detect subclonal disease that might predispose patients to relapse but that might be missed by MFC, either because of a lack of sensitivity of the flow cytometry assay or because of immunophenotypic shifting of the relapsing clone. 22 In contrast to acute myeloid leukemia, in which clonal heterogeneity and clonal evolution leading to relapse are well established, 23, 24 less is known about subclonality in adult ALL. It is possible that patients with exposure to more prior therapies have an increased likelihood of resistant subclones that persist below the level of detection of the MFC-based MRD assay. Future studies evaluating the clonal heterogeneity of relapsed/refractory ALL as well as the mechanisms of relapse are warranted and may provide insight into our finding of the poor predictive value of MFC in the S2 population.
Ultimately, regardless of the reason for the differential prognostic impact of MRD according to the salvage status, our findings strongly support the strategy of using the most effective available therapy (eg, blinatumomab and inotuzumab) at the time of first relapse and then SCT for responding patients with an adequate donor. These data suggest that the same depth of response, as assessed by MFC (ie, MRD negativity), leads to divergent survival outcomes for these 2 groups of patients. For patients in S2, novel treatment strategies for these patients are needed because this group has a particularly poor prognosis, regardless of the MRD response. 25 In this study, we analyzed patients treated with 1 of 3 monoclonal antibody-containing regimens: inotuzumab, blinatumomab, and HCVD1ino. Inotuzumab and blinatumomab have shown significant promise in the management of relapsed/refractory ALL and appear to improve outcomes in comparison with historical data for chemotherapy-only regimens. 7, 26 The apparently improved survival observed with these novel monoclonal antibodies may be in part mediated through the higher MRD negativity rates achieved with these regimens in comparison with standard cytotoxic chemotherapy. 27 For example, in a long-term follow-up of patients who received blinatumomab in the salvage setting, an MRD response was associated with a 67% reduction in the risk of death. 15 In studies of patients who remained MRDpositive after the initial treatment or developed MRD relapse, blinatumomab has been shown to be particularly effective in eliminating MRD; this appears to translate into improved survival among MRD responders. 28 Our findings suggest that an MRD response in the salvage setting may translate into improved outcomes among patients treated with novel monoclonal antibody-based regimens. However, whether MRD-directed therapies for patients who remain MRD-positive after salvage treatment will also improve outcomes needs to be evaluated in prospective studies.
Our study has several limitations. Although we identified strong trends toward improved survival for patients who achieved MRD negativity (especially those in S1), these analyses did not reach statistical significance, likely because of the relatively small sample size. Furthermore, we were not able to assess the optimal timing of MRD assessment in the salvage setting because MRD was measured only at the time of remission. In the frontline setting, the prognostic impact of an MRD response varies with the timing of the MRD assessment; therefore, future studies to evaluate this issue in patients with relapsed/refractory disease are warranted. 29 Finally, the finding that relapses were still frequent among patients who achieved MRD negativity highlights the importance of developing newer, more sensitive assays for MRD.
In conclusion, patients with relapsed/refractory ALL who achieve MRD negativity in S1 have improved outcomes and can achieve excellent long-term survival, especially if SCT is performed. The achievement of MRD negativity is an important therapeutic outcome in the
